journal article·2024-02Open access

Manganese@Albumin Nanocomplex and Its Assembled Nanowire Activate TLR4‐Dependent Signaling Cascades of Macrophages

Shuodan Huang, Yan Gao, Huiying Li, Ruoran Wang, Xiaomei Zhang, Xiaoyu Wang, Di Huang, Linxuan Zhang, Hélder A. Santos, Zhenyu Yin, Bing Xia

Advanced Materials· Volume 36· Issue 5

Abstract

Abstract The immunomodulatory effect of divalent manganese cations (Mn2+), such as activation of the cGAS−STING pathway or NLRP3 inflammasomes, positions them as adjuvants for cancer immunotherapy. In this study, it is found that trace Mn2+ ions, bound to bovine serum albumin (BSA) to form Mn@BSA nanocomplexes, stimulate pro‐inflammatory responses in human‐ or murine‐derived macrophages through TLR4‐mediated signaling cascades. Building on this, the assembly of Mn@BSA nanocomplexes to obtain nanowire structures enables stronger and longer‐lasting immunostimulation of macrophages by regulating phagocytosis. Furthermore, Mn@BSA nanocomplexes and their nanowires efficiently activate peritoneal macrophages, reprogramme tumor‐associated macrophages, and inhibit the growth of melanoma tumors in vivo. They also show better biosafety for potential clinical applications compared to typical TLR4 agonists such as lipopolysaccharides. Accordingly, the findings provide insights into the mechanism of metalloalbumin complexes as potential TLR agonists that activate macrophage polarization and highlight the importance of their nanostructures in regulating macrophage‐mediated innate immunity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immune cells in cancer · Extracellular vesicles in disease · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Science, State Key Laboratory of Tree Genetics and Breeding Nanjing Forestry University Nanjing 210037 China

Geriatric Department Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Nanjing 210008 P. R. China

School of Pharmacy China Pharmaceutical University Nanjing 211198 P. R. China

Department of Biomedical Engineering University Medical Center Groningen/University of Groningen Ant. Deusinglaan 1 Groningen 9713 AV The Netherlands

W.J. Kolff Institute for Biomedical Engineering and Materials Science University Medical Center Groningen/University of Groningen Ant. Deusinglaan 1 Groningen 9713 AV The Netherlands

Drug Research Program Division of Pharmaceutical Chemistry and Technology Faculty of Pharmacy University of Helsinki Helsinki FI‐00014 Finland

Funding

Academy of Finland · National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province

References (58)

Show source-provided references
1. 10.1016/j.it.2014.05.00110.1016/j.it.2014.05.001 ↗
2. Li J. · Zhongguo Kexue: Huaxue · 2019 · 49 · 1037
3. 10.1016/bs.ai.2019.11.00710.1016/bs.ai.2019.11.007 ↗
4. 10.1016/j.celrep.2020.10805310.1016/j.celrep.2020.108053 ↗
5. 10.1016/j.isci.2022.10535210.1016/j.isci.2022.105352 ↗
6. Wang C. · Immunity · 2018 · 48 · 657
7. 10.1016/j.matt.2022.08.02610.1016/j.matt.2022.08.026 ↗
8. 10.1126/scisignal.aat990010.1126/scisignal.aat9900 ↗
9. 10.1038/s41565-021-00962-910.1038/s41565-021-00962-9 ↗
10. 10.1002/adma.20220540910.1002/adma.202205409 ↗
11. Fan H. · Coord. Chem. Rev. · 2023 · 480
12. 10.1016/j.nantod.2022.10158310.1016/j.nantod.2022.101583 ↗
13. Zhu Y. · Sci. Adv. · 2022 · 8
14. 10.1016/j.ccr.2021.21434510.1016/j.ccr.2021.214345 ↗
15. 10.1021/acs.chemrev.8b0039610.1021/acs.chemrev.8b00396 ↗
16. 10.1038/s41423-021-00669-w10.1038/s41423-021-00669-w ↗
17. 10.3724/abbs.202102410.3724/abbs.2021024 ↗
18. 10.1016/j.biopha.2022.11368010.1016/j.biopha.2022.113680 ↗
19. 10.1126/scisignal.aau454310.1126/scisignal.aau4543 ↗
20. 10.1016/0361-9230(90)90152-P10.1016/0361-9230(90)90152-P ↗
21. 10.1111/j.1471-4159.1993.tb02153.x10.1111/j.1471-4159.1993.tb02153.x ↗
22. 10.1002/adma.20160003810.1002/adma.201600038 ↗
23. 10.1016/j.jconrel.2022.11.03410.1016/j.jconrel.2022.11.034 ↗
24. 10.1016/j.addr.2018.07.01110.1016/j.addr.2018.07.011 ↗
25. 10.1016/j.jconrel.2020.10.03010.1016/j.jconrel.2020.10.030 ↗
26. 10.1021/acs.molpharmaceut.1c0004610.1021/acs.molpharmaceut.1c00046 ↗
27. 10.1038/s41467-017-02191-y10.1038/s41467-017-02191-y ↗
28. 10.1016/j.tibs.2020.08.00310.1016/j.tibs.2020.08.003 ↗
29. 10.1016/j.biomaterials.2021.12070910.1016/j.biomaterials.2021.120709 ↗
30. 10.1007/s12039-016-1184-z10.1007/s12039-016-1184-z ↗
31. 10.1002/smll.20170064010.1002/smll.201700640 ↗
32. 10.1039/C9TB02341K10.1039/C9TB02341K ↗
33. 10.1021/acsnano.2c0743910.1021/acsnano.2c07439 ↗
34. 10.1038/s41467-022-33301-010.1038/s41467-022-33301-0 ↗
35. 10.1016/j.jddst.2022.10386910.1016/j.jddst.2022.103869 ↗
36. 10.1002/ppsc.20210001310.1002/ppsc.202100013 ↗
37. 10.1021/nn506238610.1021/nn5062386 ↗
38. Hodoroaba V. · 2019
39. Sur U. K. · 2019
40. Jachimska B. · Langmuir · 2021 · 5 · 6866
41. 10.1038/s41570-020-00244-310.1038/s41570-020-00244-3 ↗
42. 10.1038/4460510.1038/44605 ↗
43. 10.1084/jem.2002219410.1084/jem.20022194 ↗
44. 10.1016/j.ejmech.2022.11429110.1016/j.ejmech.2022.114291 ↗
45. 10.1016/j.pharmthera.2021.10791810.1016/j.pharmthera.2021.107918 ↗
46. Abbas A. K. · 2022
47. 10.1038/nri203810.1038/nri2038 ↗
48. 10.1016/j.abb.2018.12.02210.1016/j.abb.2018.12.022 ↗
49. 10.1038/nri324410.1038/nri3244 ↗
50. 10.1038/s41565-021-00858-810.1038/s41565-021-00858-8 ↗
51. 10.1021/acs.chemrev.7b0019410.1021/acs.chemrev.7b00194 ↗
52. 10.1016/j.diff.2022.10.00110.1016/j.diff.2022.10.001 ↗
53. 10.1002/adma.20210801210.1002/adma.202108012 ↗
54. 10.3390/ijerph1619354610.3390/ijerph16193546 ↗
55. 10.1039/D2SC06036A10.1039/D2SC06036A ↗
56. 10.1016/j.it.2019.02.00310.1016/j.it.2019.02.003 ↗
57. 10.1038/nnano.2016.16810.1038/nnano.2016.168 ↗
58. 10.1002/adma.20220759310.1002/adma.202207593 ↗